Prevenar 13™

Phase 3Small molecule

GSK

Prevenar 13™ is one of 35 small molecule programs targeting Clinical Trial. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clinical TrialActive, not recruiting

Clinical TrialPhase 3

Active, not recruiting

Competition

Competitive Landscape

127 competitors in Clinical Trial

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

3 2

Venclexta

AbbVie

Phase 3

2 3

Avelox

Bayer

Phase 3

2 4

Paraplatin

AAvyxa

Phase 3

2 5

Potassium Iodide

MMeda Pharmaceuticals

Phase 3

1 6

Opzelura

DDizal Pharmaceuticals

Phase 3

1 7

Ablysinol

CSL Behring

Phase 3

1 8

Nascobal

GGrupo Espanol de Tumores Neuroendocrinos

Phase 3

1 9

Alkeran

AApotex Inc.

Phase 2

1 10

Glucocorticoids

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity11 trials

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04016714·1,191 enrolled

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01341639·1,250 enrolled

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

Completed·GGPN Vaccines·Phase 1·NCT05667740·118 enrolled

Show 8 more trials

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Completed· GSK logo

GSK·Phase 2·NCT01453998·657 enrolled

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants

Completed· GSK logo

GSK·Phase 2·NCT01204658·576 enrolled

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Completed· GSK logo

GSK·Phase 2·NCT01248884·721 enrolled

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01480258·1,315 enrolled

Extension Safety and Immunogenicity Study of GPNV-001

Completed·GGPN Vaccines·Phase 1/2·NCT05982314·60 enrolled

Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants

Completed·PPATH·Phase 1/2·NCT02308540·346 enrolled

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04031846·1,184 enrolled

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Completed· Pfizer logo

Pfizer·Phase 3·NCT01939158·803 enrolled

Vaccine5 trials

Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants

Completed·PPATH·Phase 3·NCT03896477·660 enrolled

Pneumococcal Vaccine in Untreated CLL Patients

Completed·KKarolinska University Hospital·Phase 3·NCT01892618·134 enrolled

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Completed· GSK logo

GSK·Phase 2·NCT01090453·480 enrolled

Show 2 more trials

Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos

Completed· Pfizer logo

Pfizer··NCT01396434·3,006 enrolled

Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD

Terminated·—·Phase 2·NCT02255227·104 enrolled

Vaccination3 trials

Pneumococcal Vaccination of Crohn Patients

Completed·SStatens Serum Institut·Phase 4·NCT01947010·151 enrolled

Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™

Completed· GSK logo

GSK·Phase 3·NCT01641133·457 enrolled

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Completed· Sanofi logo

Sanofi·Phase 3·NCT01839175·350 enrolled

Sepsis1 trial

Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors

Completed·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT03565159·214 enrolled

Clinical Trial1 trial

Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants

Active, not recruiting·FFosun Adgenvax Biopharmaceutical Co.,Ltd.·Phase 3·NCT05759520·1,800 enrolled

6 more indications

Rheumatoid Arthritis1 trial

VACcination In Methotrexate Treated Rheumatoid Arthritis Patients

Completed·UUniversity Hospital, Montpellier·Phase 3·NCT01942174·276 enrolled

Influenza1 trial

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Completed· GSK logo

GSK·Phase 3·NCT01439360·12,046 enrolled

Pneumococcal Vaccines1 trial

Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines

Completed·UUniversity of Oxford·Phase 3·NCT01432158·4 enrolled

Rotavirus Vaccine1 trial

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

Completed· GSK logo

GSK·Phase 3·NCT03207750·1,280 enrolled

Vaccines1 trial

Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology

Completed·MMikhael Petrovich Kostinov·Phase 4·NCT02787863·219 enrolled

Unspecified1 trial

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01839188·385 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Prevenar 13™. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prevenar 13™ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prevenar 13™. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Prevenar 13™

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunogenicity11 trials

Vaccine5 trials

Vaccination3 trials

Sepsis1 trial

Clinical Trial1 trial

Rheumatoid Arthritis1 trial

Influenza1 trial

Pneumococcal Vaccines1 trial

Rotavirus Vaccine1 trial

Vaccines1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News